Palisade Bio Reports Q1 2026 Results with Increased R&D Expenses

Palisade Bio (NASDAQ:PALI) reported a significant increase in research and development expenses to $6.4 million for the first quarter of 2026, up from $1.0 million in the same period last year. The company attributed this rise to higher costs related to clinical trials, employee compensation, and manufacturing processes for its lead drug candidate, PALI-2108.

By Maham Fatima Mon, May 18, 2026 at 7:49 AM GMT+3 2 min read · Yahoo Finance · May 18, 2026, 04:49 UTC

Tickers: $PALI

Topics: biopharmaceutical clinical trials PDE4 inhibitor R&D expenses

Read the full article at Yahoo Finance

More World news

Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC
Nvidia, Supermicro, and Megaspeed Face U.S. Department of Justice Probes Seeking Alpha · November 12, 2026, 17:00 UTC
Starbucks Implements Quarterly Performance-Based Bonuses for Baristas Seeking Alpha · November 12, 2026, 17:03 UTC
Jim Cramer Analyzes Nvidia Leadership Transition and Recommends AMD, Constellation Brands, and Kimberly-Clark CNBC · November 12, 2026, 16:55 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Threatening $500 Billion AI Financing Plan CNBC · November 12, 2026, 16:55 UTC
Al Mouj Muscat Receives Three Architectural Awards at International and Arabian Property Awards 2026 PR Newswire · November 12, 2026, 17:01 UTC
SoftBank Reports $7.1 Billion Quarterly Loss Driven by Natural Gas Turbine Over-Ordering TechCrunch · November 12, 2026, 17:00 UTC
PayPal and Kiva Renew Long-Term Partnership to Support Global Microloans PR Newswire · November 12, 2026, 17:00 UTC
Tesla to Discontinue Cybertruck Production by Summer 2027 to Prioritize Cybercab The Verge · November 12, 2026, 17:00 UTC
Absci Reports Q3 2026 Financial Results and Clinical Updates for ABS-201 Motley Fool · November 12, 2026, 16:54 UTC